T 1525/10 (Sustained release of fluvastatin/NOVARTIS AG) of 20.9.2011

European Case Law Identifier: ECLI:EP:BA:2011:T152510.20110920
Date of decision: 20 September 2011
Case number: T 1525/10
Application number: 97944240.7
IPC class: A61K 9/20
A61K 31/19
Language of proceedings: EN
Distribution: C
Download and more information:
Decision text in EN (PDF, 43 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Pharmaceutical compositions for sustained release of the HMG-CoA reductase inhibitor fluvastatin
Applicant name: Novartis AG
Novartis Pharma GmbH
Opponent name: Ratiopharm GmbH
Actavis UK Ltd
Actavis GmbH
Mylan S.A.S.
Board: 3.3.02
Headnote: -
Relevant legal provisions:
European Patent Convention Art 84
European Patent Convention Art 123(2)
Rules of procedure of the Boards of Appeal Art 12(4)
Keywords: Main request and auxiliary request I - clarity (no): parameter and method for measuring it not clearly defined
Auxiliary request I - Article 123(2) EPC (no): unallowable generalisation
Auxiliary request II - admission (no): request withdrawn in first instance proceedings
Catchwords:

-

Cited decisions:
G 0009/92
G 0004/93
G 0002/97
R 0011/08
R 0011/11
T 0240/04
T 0390/07
T 1469/07
T 1705/07
T 0023/10
Citing decisions:
T 1912/09
T 0937/11
T 1176/12
T 1697/12
T 0450/13
T 0467/13
T 1678/13
T 0143/14
T 0052/15
T 0670/16
T 0378/17
T 1497/17

21 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

Offical Journal of the EPO

Case Law Book: V Priority

Case Law of the Enlarged Board

General Case Law